THOUSAND OAKS, Calif., Dec. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies at the 54th Annual Meeting of the American Society of Hematology (ASH) from Dec. 8-11, 2012, in Atlanta. These include updated results from a Phase 2 trial evaluating blinatumomab in B-precursor acute lymphoblastic leukemia (ALL) and data evaluating long-term use of Nplate ® (romiplostim) in pediatric chronic immune thrombocytopenia (ITP).
"The research we are presenting at this year's annual meeting of the American Society of Hematology reflects Amgen's ongoing commitment to develop medicines for patients with the greatest need for treatment options," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Our data show exciting progress in fighting hematologic diseases, particularly in orphan diseases like ALL and ITP."
ABSTRACTS OF INTEREST INCLUDE:Abstracts are currently available on the ASH website at www.hematology.org. Updated data will be presented at the meeting.
Blinatumomab (AMG 103) in B-precursor Acute Lymphoblastic Leukemia (ALL)
- Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Results from a Phase 2 Single-arm Dose-ranging TrialLead Author: Max S. Topp, Department of Internal Medicine II, Division of Hematology and Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, GermanyAbstract No. 670Oral Presentation: Monday, Dec. 10, 4:30 p.m. – 6:00 p.m. EST, A103, Level 1, Building A
- Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP): Results from an Open-label Phase 1/2 Randomized Double-blind Placebo-controlled Study. Lead Author: James B. Bussel, Department of Pediatrics, Division of Hematology, Weill Medical College of Cornell University, New York, NYAbstract No. 621Oral Presentation: Monday, Dec. 10, 4:30 p.m. – 6:00 p.m. EST, Georgia Ballroom 3, Level 3, Building C
- Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim: Results from a Safety Analysis of Pooled Data from ITP Romiplostim Clinical StudiesLead Author: Douglas B. Cines, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PAAbstract No. 2185Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
- A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies: Results from a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Thrombopoietin-receptor Agonists (TPOr)Lead Author: Wendy Langeberg, Amgen, Thousand Oaks, CAAbstract No. 2187Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
- Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study Lead Author: Dominik Selleslag, Department of Hematology, AZ St-Jan, Brugge, BelgiumAbstract No. 3316Poster Presentation: Monday, Dec. 10, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
- Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study Lead Author: Hagop M. Kantarjian, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXAbstract No. 421Oral Presentation: Monday, Dec. 10, 10:30 a.m. – 12:00 p.m. EST, B216-B217, Level 2, Building B
- Development and Validation of a Model to Predict Response to Romiplostim in Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Placebo-controlled Study Lead Author: Mikkael A. Sekeres, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHAbstract No. 2801Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
- Clinical and Economic Burden During Hospitalizations Among Cancer Patients with Febrile Neutropenia: Evidence From U.S. Hospitals, 2007-2010Lead Author: Brian Dulisse, Premier Healthcare Alliance, Charlotte, NCAbstract No. 239Oral Presentation: Sunday, Dec. 9, 4:30 p.m. – 6:00 p.m. EST, C211-C213, Level 2, Building C
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV